Essential Planning LLC. bought a new stake in shares of Psyence Biomedical Ltd. (NASDAQ:PBM – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 73,278 shares of the company’s stock, valued at approximately $163,000. Essential Planning LLC. owned 1.11% of Psyence Biomedical at the end of the most recent reporting period.
Psyence Biomedical Stock Performance
Shares of NASDAQ:PBM opened at $0.76 on Friday. Psyence Biomedical Ltd. has a 1 year low of $0.74 and a 1 year high of $140.25. The business has a 50 day simple moving average of $1.43 and a two-hundred day simple moving average of $5.70.
Psyence Biomedical (NASDAQ:PBM – Get Free Report) last announced its earnings results on Thursday, January 23rd. The company reported $0.51 earnings per share (EPS) for the quarter.
Psyence Biomedical Company Profile
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.
Featured Articles
- Five stocks we like better than Psyence Biomedical
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Growth Stocks: What They Are, What They Are Not
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- The 3 Best Blue-Chip Stocks to Buy Now
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Want to see what other hedge funds are holding PBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Psyence Biomedical Ltd. (NASDAQ:PBM – Free Report).
Receive News & Ratings for Psyence Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psyence Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.